Expecting the worst increases side-effects in breast cancer patients on hormone therapies

August 22, 2016, European Society for Medical Oncology

A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer has found that the number and seriousness of side-effects they experienced were influenced by their expectations.

The study, which is published in the leading cancer journal Annals of Oncology today, found that women who had higher expectations of suffering more and worse side-effects before their treatment began did, in fact, experience more after two years of adjuvant hormone therapy. They experienced nearly twice the number of side-effects than did women with positive expectations or who thought the effects would not be too bad.

The researchers say that their findings are important because women may stop taking their adjuvant hormone treatment if they experience too many side-effects and worse health-related quality of life; this, in turn, can affect the success of treatment and survival. However, if expectations can predict the risk of experiencing side-effects, then interventions such as counselling could lower the risk and, therefore, improve adherence to medication.

Professor Yvonne Nestoriuc, of the Department of Psychosomatic Medicine and Psychotherapy at the University Medical Centre, Hamburg, Germany, who led the study, said: "Our results show that expectations constitute a clinically relevant factor that influences the long-term outcome of hormone therapy. Expectations can be modified so as to decrease the burden of long-term side-effects and optimise adherence to preventive anti-cancer treatments in survivors."

The research was carried out in 111 women who were enrolled in a clinical trial at the Breast Cancer Centre at the University of Marburg, Germany, who had had surgery for hormone receptor positive breast cancer and who were scheduled to start adjuvant hormone therapy with tamoxifen or aromatase inhibitors such as exemestane.

The researchers questioned the patients about their expectations of the effect of taking adjuvant hormone therapy at the start of the trial, and then assessed them at three months (107 women) and at two years (88 women).

At the start of the trial nine patients (8%) said they expected no side-effects from adjuvant hormone treatment; 70 patients (63%) said they expected mild side-effects, and 32 patients (29%) expected moderate to severe side-effects.

After three months, patients who later dropped out of the trial (19) reported significantly more side-effects than those who remained in it (88). At the end of the two years, adherence to medication was associated with side-effects at three months and expectations at the beginning of the trial. Two-year adherence rates were higher in women with low expectations of side-effects before treatment started (87% adherence), than in women with high expectations of side-effects (69%). Higher expectations of side-effects at the start of the study predicted a 1.8 increase in their occurrence after two years and a lower health-related quality of life when compared to women expecting no or mild side-effects. The researchers adjusted their findings to take account of factors that could affect the results, such as sociodemographic and medical factors, including symptoms the women were already experiencing at the start of the study, and previous menopausal symptoms. After these adjustments, expectations were still shown to be independent and clinically relevant factors.

Side-effects included joint pain (71%), weight gain (53%) and hot flushes (47%). But women also reported symptoms that could not be directly attributable to their medication; these included back pain (31%), breathing problems (28%) and dizziness (26%). "This substantiates the conclusion that psychological mechanisms such as negative expectations about the treatment play a significant role in the side-effects breast cancer patients experience," said Prof Nestoriuc. "Higher negative expectations, formed by patients before the start of their adjuvant therapy, seem to have a pronounced influence on long-term tolerability, especially once they are confirmed by initially high side-effects after three months."

A limitation of the study was that nearly 40% of patients who were eligible to join the trial did not take part. Their decision might have been affected by the fact that they already had negative expectations about adjuvant .

Prof Nestoriuc and her colleagues are currently carrying out a randomised controlled trial to see whether strategies for improving 's expectations are effective. These include counselling by psychologists or trained medical staff just before the start of treatment as well as during the first couple of months, information on that highlights its benefits, that also explains about the possible effects of expectations, and that gives strategies for coping with side-effects.

Explore further: No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen

More information: "Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a two-year prospective clinical cohort study", by Y. Nestoriuc et al. Annals of Oncology, DOI: 10.1093/annonc/mdw266

Related Stories

No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen

December 11, 2015
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two ...

Breast cancer patients likely to skip follow-up therapy if not treating other chronic ills

June 9, 2016
Researchers at Columbia University's Mailman School of Public Health and Columbia University Medical Center found that patients who did not adhere to their medication schedule for chronic conditions, such as hypertension, ...

Sleep hormone melatonin helps breast cancer drug kill more cancer cells

June 14, 2016
Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects. In a new study published in Colloids and Surfaces ...

What factors affect non-compliance with endocrine therapy among young women with breast cancer?

February 16, 2016
A new study from Harvard Medical School of young women with hormone receptor-positive (HR+) breast cancer showed that more than half did not believe endocrine therapy was essential, even though it has been proven to reduce ...

Male breast cancer patients stop taking tamoxifen early because of drug-related side effects

November 16, 2011
The largest study to investigate the tolerability of the breast cancer drug tamoxifen in male breast cancer patients has shown that men stop taking their prescribed therapy early because of problems with side effects caused ...

Major clinical trial led to steep declines in use of an ineffective breast cancer treatment

July 7, 2016
Many common medical treatments have never been tested in a clinical trial. A new study published in the July issue of Health Affairs highlights how evidence from trials of untested but widely used treatments can change medical ...

Recommended for you

New drugs are improving survival times for patients with aggressive type of blood cancer, study finds

June 25, 2018
Survival times for a highly aggressive type of blood cancer have nearly doubled over the last decade due to the introduction of new targeted drugs, a Yorkshire study has shown.

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...

Higher body fat linked to lower breast cancer risk in younger women

June 21, 2018
While obesity has been shown to increase breast cancer risk in postmenopausal women, a large-scale study co-led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher found the opposite is true ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.